Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma

Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment... Oncol Ther (2016) 4:239–256 DOI 10.1007/s40487-016-0030-2 ORIGINAL RESEARCH Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma . . Jordan Amdahl Lei Chen Thomas E. Delea Received: May 18, 2016 / Published online: September 27, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com systematic literature reviews. HRs for PFS and ABSTRACT OS (adjusted for crossover as appropriate) were Introduction: The present study aimed to analyzed using multivariate and univariate inform an economic evaluation of dabrafenib Bayesian network meta-analysis. and trametinib combination as first-line Results: In multivariate network-meta analyses treatment of metastatic melanoma in a (HRs for PFS and OS estimated simultaneously Canadian setting. A network meta-analysis was to account for the correlation of treatment conducted to estimate hazard ratios (HRs) for effects on PFS and OS), HRs (95% credible progression-free survival (PFS)and overall interval) for PFS and OS favored dabrafenib survival (OS) of dabrafenib plus trametinib plus trametinib [PFS: 0.23 (0.18–0.29) versus versus other first-line treatments of BRAF DTIC, 0.32 (0.24–0.42) versus ipilimumab plus mutation-positive metastatic melanoma DTIC, 0.52 (0.32–0.83) versus trametinib, 0.57 including dabrafenib, trametinib, vemurafenib, (0.48–0.69) versus vemurafenib, and 0.59 ipilimumab, and dacarbazine (DTIC). (0.50–0.71) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma

Oncology and Therapy , Volume 4 (2) – Sep 27, 2016

Loading next page...
 
/lp/springer-journals/network-meta-analysis-of-progression-free-survival-and-overall-rsQFisYRUR
Publisher
Springer Journals
Copyright
Copyright © 2016 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-016-0030-2
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2016) 4:239–256 DOI 10.1007/s40487-016-0030-2 ORIGINAL RESEARCH Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma . . Jordan Amdahl Lei Chen Thomas E. Delea Received: May 18, 2016 / Published online: September 27, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com systematic literature reviews. HRs for PFS and ABSTRACT OS (adjusted for crossover as appropriate) were Introduction: The present study aimed to analyzed using multivariate and univariate inform an economic evaluation of dabrafenib Bayesian network meta-analysis. and trametinib combination as first-line Results: In multivariate network-meta analyses treatment of metastatic melanoma in a (HRs for PFS and OS estimated simultaneously Canadian setting. A network meta-analysis was to account for the correlation of treatment conducted to estimate hazard ratios (HRs) for effects on PFS and OS), HRs (95% credible progression-free survival (PFS)and overall interval) for PFS and OS favored dabrafenib survival (OS) of dabrafenib plus trametinib plus trametinib [PFS: 0.23 (0.18–0.29) versus versus other first-line treatments of BRAF DTIC, 0.32 (0.24–0.42) versus ipilimumab plus mutation-positive metastatic melanoma DTIC, 0.52 (0.32–0.83) versus trametinib, 0.57 including dabrafenib, trametinib, vemurafenib, (0.48–0.69) versus vemurafenib, and 0.59 ipilimumab, and dacarbazine (DTIC). (0.50–0.71)

Journal

Oncology and TherapySpringer Journals

Published: Sep 27, 2016

References